Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder.

Sajatovic M, Levin JB, Sams J, Cassidy KA, Akagi K, Aebi ME, Ramirez LF, Safren SA, Tatsuoka C.

Bipolar Disord. 2015 Sep;17(6):653-61. doi: 10.1111/bdi.12326.

PMID:
26529124
2.

Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA.

Kishimoto H, Maehara M.

Arch Osteoporos. 2015;10:231. doi: 10.1007/s11657-015-0231-6. Epub 2015 Aug 22.

3.

Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.

Yun H, Curtis JR, Guo L, Kilgore M, Muntner P, Saag K, Matthews R, Morrisey M, Wright NC, Becker DJ, Delzell E.

BMC Musculoskelet Disord. 2014 Apr 1;15:112. doi: 10.1186/1471-2474-15-112.

4.

Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions.

Marcus JL, Buisker T, Horvath T, Amico KR, Fuchs JD, Buchbinder SP, Grant RM, Liu AY.

HIV Med. 2014 Aug;15(7):385-95. doi: 10.1111/hiv.12132. Epub 2014 Feb 24. Review.

5.

Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study.

Tüzün Ş, Akyüz G, Eskiyurt N, Memiş A, Kuran B, İçağasıoğlu A, Sarpel T, Özdemir F, Özgirgin N, Günaydın R, Cakçı A, Yurtkuran M.

Int J Med Sci. 2013 Nov 20;10(13):1880-7. doi: 10.7150/ijms.5359. eCollection 2013.

6.

Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database.

Fan T, Zhang Q, Sen SS.

Clinicoecon Outcomes Res. 2013 Nov 19;5:589-95. doi: 10.2147/CEOR.S39076. eCollection 2013.

7.

Improving treatment adherence in patients with rheumatologic disease.

de Achaval S, Suarez-Almazor ME.

J Musculoskelet Med. 2010 Oct 12;27(10). pii: 1691476.

8.

Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review.

Chiu CK, Kuo MC, Yu SF, Su BY, Cheng TT.

BMC Musculoskelet Disord. 2013 Sep 23;14:276. doi: 10.1186/1471-2474-14-276.

9.

Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study.

Migliaccio S, Resmini G, Buffa A, Fornari R, Di Pietro G, Cerocchi I, Dormi A, Gimigliano F, Mulè R, Celi M, Frigato M, Lenzi A, Tarantino U, Iolascon G, Malavolta N.

Clin Cases Miner Bone Metab. 2013 Jan;10(1):56-60. doi: 10.11138/ccmbm/2013.10.1.056.

10.

Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis.

Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, De Geest S, Dobbels F, Lewek P, Urquhart J, Vrijens B; ABC project team.

Drugs. 2013 May;73(6):545-62. doi: 10.1007/s40265-013-0041-3. Review.

11.

Osteoporosis medication adherence: physician perceptions vs. patients' utilization.

Curtis JR, Cai Q, Wade SW, Stolshek BS, Adams JL, Balasubramanian A, Viswanathan HN, Kallich JD.

Bone. 2013 Jul;55(1):1-6. doi: 10.1016/j.bone.2013.03.003. Epub 2013 Mar 15.

12.

Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Lewiecki EM.

Ther Adv Chronic Dis. 2010 May;1(3):115-28. doi: 10.1177/2040622310374783.

13.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

14.

Medical treatment of osteoporotic vertebral fractures.

Langdahl BL, Harsløf T.

Ther Adv Musculoskelet Dis. 2011 Feb;3(1):17-29. doi: 10.1177/1759720X10392105.

15.

Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.

Curtis JR, Yun H, Matthews R, Saag KG, Delzell E.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):1054-60. doi: 10.1002/acr.21638.

16.

Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.

Schousboe JT, Bauer DC.

Curr Osteoporos Rep. 2012 Mar;10(1):56-63. doi: 10.1007/s11914-011-0091-y. Review.

17.

If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.

Adachi JD, Josse RG, Russell RG.

Ther Clin Risk Manag. 2011;7:181-98. doi: 10.2147/TCRM.S17513. Epub 2011 May 24.

18.

Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.

Netelenbos JC, Geusens PP, Ypma G, Buijs SJ.

Osteoporos Int. 2011 May;22(5):1537-46. doi: 10.1007/s00198-010-1372-5. Epub 2010 Sep 14.

19.

Oral bisphosphonate compliance and persistence: a matter of choice?

Silverman SL, Schousboe JT, Gold DT.

Osteoporos Int. 2011 Jan;22(1):21-6. doi: 10.1007/s00198-010-1274-6. Epub 2010 May 11. Review.

20.

Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial.

Shu AD, Stedman MR, Polinski JM, Jan SA, Patel M, Truppo C, Breiner L, Chen YY, Weiss TW, Solomon DH.

Am J Manag Care. 2009 Jul;15(7):417-24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk